Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 8/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.45 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3787151 | 0.91 | MEN1 (0.44) | NPY5RKCNH2USP30MEN1NPC1 | |
| SCHEMBL7962507 | 0.82 | NPY5R (0.60) | NPY5RKCNH2MEN1NPC1RAB9A | |
| SCHEMBL7969172 | 0.82 | NPC1 (0.53) | NPY5RKCNH2MEN1NPC1RAB9A | |
| SCHEMBL10140665 | 0.80 | MEN1 (0.45) | NPY5RKCNH2MEN1NPC1RAB9A | |
| SCHEMBL7973223 | 0.79 | NPY5R (0.62) | NPY5RKCNH2ADRA1A | |
| SCHEMBL7970001 | 0.79 | GFER (0.56) | NPY5RUSP30MEN1NPC1RAB9A | |
| SCHEMBL7973969 | 0.78 | CHEK2 (0.57) | NPY5RCHEK2PKN1PKN2 | |
| SCHEMBL7976233 | 0.77 | PRSS1 (0.52) | NPY5RCHEK2 | |
| SCHEMBL3791087 | 0.75 | NPC1 (0.47) | NPY5RKCNH2MEN1NPC1RAB9A | |
| SCHEMBL7973178 | 0.73 | NPY5R (0.56) | NPY5RMEN1KMT2APKN1PKN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2805939-B1 | Heterocyclic compounds as factor IXA inhibitors. | MERCK SHARP & DOHME (US) | 2018-06-27 | — | — | EP | disclosed |
| EP-2805939-A1 | Heterocyclic compounds as factor IXA inhibitors. | Merck Sharp & Dohme Corp. (US) | 2014-11-26 | — | — | EP | disclosed |
| US-8148363-B2 | Heterocyclic compounds as factor IXA inhibitors | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148363-B2 | Heterocyclic compounds as factor IXA inhibitors | SCHERING CORPORATION (US) | 2012-04-03 | — | — | US | disclosed |
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-17 | — | — | US | disclosed |
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-03-17 | — | — | US | disclosed |
| WO-2009143039-A2 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | SCHERING CORPORATION (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065682-A1 | HETEROCYCLIC COMPOUNDS AS FACTOR IXA INHIBITORS | F9, F12, F8 | NPY5R 652/4885KCNH2 2017/4885PIN1 1083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.